As both he and PM Modi are from the same state, it makes him the easy target of baseless allegations, says Adani
Brokerages have a mixed outlook on margin trajectory for the sector
The combined entity will have a market share of more than 50 per cent in India's organised mattress space
Industry players say some companies plan to re-file their DRHPs so that they can have another stab at listing
SARFAESI and Debt Recovery Tribunals have yielded recovery rates comparable to the IBC mechanism, says Trend and Progress Report
Mid-market firms with revenues of $10 million to $1 billion faced 45% of attacks; only 21% were large ones with over $1 billion in revenue; smaller firms suffered 34% of attacks
Keeps adequate inventory levels for now; onboards multiple vendors to mitigate risk
Thousands lost jobs amid deepening funding winter in 2022 as massive layoffs by the tech companies this year alone surpassed the levels from the Great Recession
The top court's order and cash-for-loans scandal later, rocked the group across verticals; its fate now hinges on SC's ruling on bankruptcy even as the quid pro quo case involving Kocchars goes on
India Inc is gearing up for a slugfest next year and from tech to paints, new battlegrounds are emerging
Some firms braved the headwinds and stepped on the gas, others played it safe; green energy turned a bright spot
The Commission in 2018 had found DLF in contravention of the Competition Act for abusing its dominant position and discriminatory practices
Assessee appealed it was denied benefit of treaty on capital gains from share transfer
Shares of GMM Pfaudler fell as much as 18.1%, their worst intraday percentage fall in nearly five years, after a report said that one of its promoters will sell the bulk of its stake
"This step is in the right direction in embracing progressive corporate governance practices," HUL said in its statement
Delhi-based company says its business gained after countries eased travel restrictions for Covid-19
The company is seeking a restructuring of the loan, but it faced steep losses. Around this time, some activist investors bought some of the bonds
Proposed Settlement and commitment mechanism
Both firms own 18.4% stake in Tata Sons
With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon